We performed a comprehensive analysis of the efficacy of two IDH inhibitor regimens (IDH inhibitor combination and IDH inhibitor alone) in two populations (newly diagnosed IDH-mutated AML patients and R/R IDH-mutated AML patients) based on treatment response and survival. The gene discussed is IDH1; the disease is acute myeloid leukemia.